DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of the Pharmacology of Tamiflu in Pregnancy

Information source: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: H1N1 Influenza Treatment During Pregnancy

Phase: N/A

Status: Completed

Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Official(s) and/or principal investigator(s):
Richard Beigi, MD, Principal Investigator, Affiliation: University of Pittsburgh
Steve Caritis, MD, Principal Investigator, Affiliation: University of Pittsburgh
Raman Venkataramanan, PhD, Principal Investigator, Affiliation: University of Pittsburgh


The purpose of this study is to determine the pharmacokinetics (PK) of the anti-flu medication, Tamiflu during pregnancy and to determine to what extent pregnancy may affect the currently recommended dosage of this medication.

Clinical Details

Official title: A Study of the Pharmacology of Oseltamivir (Tamiflu-Roche) in Pregnancy

Study design: Observational Model: Cohort

Primary outcome: Apparent oral clearance of oseltamivir in singletons

Secondary outcome:

Apparent oral clearance of oseltamivir in twins

Apparent renal clearance of oseltamivir carboxylate in non-pregnant women (ancillary study)

Concentration of oseltamivir carboxylate and oseltamivir at times 0 and 12h to ascertain steady state status

Plasma esterase activity. (ancillary study)

Maternal side effects -GI upset, pregnancy loss, neuropsychiatric disorder

Maternal and cord blood oseltamivir and oseltamivir carboxylate concentrations

Detailed description: The emergence of the novel H1N1 influenza virus has raised concern among public health officials and the public alike. Although initial reports suggested that the risk of serious disease or death was less than initially feared, continued experience suggests that the disease will have a major impact on the public's health. To address this urgent public health challenge, the centers of the Obstetric-Fetal Pharmacology Research Units Network (OPRU) will recruit a total of 75 pregnant women (25 per trimester with singletons pregnancies) who are receiving oseltamivir for supposed influenza infection. When possible, we will recruit women with twin gestation to determine if fetal number affects the drugs pharmacokinetics. We do not anticipated a significant number of multi-fetal gestations (< 10) but even limited data might prove useful in this population given the tremendous change in renal drug clearance that is normally seen in this group of women. An additional 25 healthy non-pregnant women will be studied to define pregnancy- related changes in the PK of oseltamivir and the carboxylate. We will study each woman once during therapy, performing steady state pharmacokinetic analyses. This study will be performed after 3 days of oral therapy to optimize the possibility that steady state concentrations have been achieved. We will: 1. collect biological fluids (plasma and urine) to further characterize the pharmacology of the drug; 2. collect a check swab for DNA to allow study of the impact of single nucleotide polymorphisms on drug handing and disease expression; 3. develop an assay or partner with others to develop an assay for oseltamivir and the primary metabolite, oseltamivir carboxylate; 4. compare the pharmacokinetics of oseltamivir and its metabolite in each trimester of pregnancy to evaluate whether gestational age has an impact on the drug's pharmacokinetics; 5. assess the impact of fetal number on the drug's pharmacokinetics; 6. ask all participants about GI tolerance to the drug and any side effects they may be experiencing, especially related to mood and psychiatric well being; and 7. on all pregnant subjects studied, when possible, we will obtain at delivery maternal and umbilical cord blood to evaluate placental transport especially in those who deliver proximate (within 3 days) to drug treatment.


Minimum age: 14 Years. Maximum age: 45 Years. Gender(s): Female.


Inclusion Criteria: 1. Taking or about to start oral oseltamivir for presumed influenza viral infection or for prophylaxis 2. Able to give informed consent 3. Pregnant female with singleton or multifetal gestation or healthy non-pregnant female (ancillary study) Exclusion Criteria: 1. Unable to take medication orally

2. Renal failure - creatinine > 1. 5

3. Hct <28

Locations and Contacts

Indiana University School of Medicine, Indianapolis, Indiana 46202, United States

University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States

University of Texas Medical Branch, Galveston, Texas 77555, United States

University of Washington, Seattle, Washington 98195, United States

Additional Information

Starting date: March 2007
Last updated: October 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017